Linifanib
Linifanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 3, cyclin-dependent kinase 19, vascular endothelial growth factor receptor 1, macrophage colony-stimulating factor 1 receptor, proto-oncogene tyrosine-protein kinase receptor Ret, mast/stem cell growth factor receptor Kit, cyclin-dependent kinase 8, vascular endothelial growth factor receptor 2, receptor-type tyrosine-protein kinase FLT3, platelet-derived growth factor receptor beta, and angiopoietin-1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 9 | — | 1 | — | — | 10 | |
| Adenocarcinoma | D000230 | — | 1 | 1 | — | — | 2 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 1 | — | — | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | 1 | — | — | 1 |
| Hepatocellular carcinoma | D006528 | C22.0 | — | — | 1 | — | — | 1 | |
| Digestive system neoplasms | D004067 | — | — | 1 | — | — | 1 | ||
| Neoplasms by histologic type | D009370 | — | — | 1 | — | — | 1 | ||
| Neoplasms by site | D009371 | — | — | 1 | — | — | 1 | ||
| Glandular and epithelial neoplasms | D009375 | — | — | 1 | — | — | 1 | ||
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 1 | 2 | — | — | — | 3 | ||
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 | ||
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Renal cell carcinoma | D002292 | — | 1 | — | — | — | 1 | ||
| Colonic neoplasms | D003110 | C18 | — | 1 | — | — | — | 1 | |
| Rectal neoplasms | D012004 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LINIFANIB |
| INN | linifanib |
| Description | Linifanib is a member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 2-fluoro-5-methylphenyl group, while the other is substituted by a p-(3-amino-1H-indazol-4-yl)phenyl group. It is a potent, selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an angiogenesis inhibitor. It is an aromatic amine, a member of indazoles and a member of phenylureas. |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 796967-16-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL223360 |
| ChEBI ID | — |
| PubChem CID | 11485656 |
| DrugBank | — |
| UNII ID | CO93X137CW (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FLT4
FLT4
CDK19
CDK19
FLT1
FLT1
CSF1R
CSF1R
RET
RET
KIT
KIT
CDK8
CDK8
KDR
KDR
FLT3
FLT3
PDGFRB
PDGFRB
TEK
TEK
Organism
Homo sapiens
Gene name
FLT4
Gene synonyms
VEGFR3
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 3
Protein synonyms
Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, fms related tyrosine kinase 4, Fms-like tyrosine kinase 4, primary congenital lymphedema, Tyrosine-protein kinase receptor FLT4, VEGF receptor-3
Uniprot ID
Mouse ortholog
Flt4 (14257)
vascular endothelial growth factor receptor 3 (P35917)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 767 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more